Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
37 participants
INTERVENTIONAL
2016-09-28
2017-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of LY2951742 in Participants With Migraine
NCT01625988
A Study of LY3451838 in Participants With Migraine
NCT04498910
Pain Biomarker Study
NCT03511846
Study in Participants With Acute Migraines Headaches
NCT00804973
Exploring Clinical Trial Experiences of Patients With Migraine
NCT05675189
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Capsaicin
Single topical dose of capsaicin
Capsaicin
Administered topically
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Capsaicin
Administered topically
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have suitable skin characteristics for the dermal capsaicin challenge
Exclusion Criteria
* Have eczema, scleroderma, psoriasis, dermatitis, keloids, tumors, ulcers, burns, flaps, or grafts on their forearm or other abnormality of the skin which may interfere with the study assessments
* Cannot avoid excess tanning (any exposure to sunlight or a tanning bed which would cause a sunburn reaction) throughout the study and cannot cover forearms for 24 hours prior to each treatment period
* Have excessive hair growth on the volar surface of the forearm or participants currently using lotions, oils, depilatory preparations, or other topical treatments on a regular basis which cannot be discontinued for the duration of the study; has used any topical treatments within 7 days of the start of the study
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Research Center
Phoenix, Arizona, United States
Pharmacology Research Institute, Newport Beach
Encino, California, United States
Parexel Early Phase Unit at Glendale
Glendale, California, United States
Pharmacology Research Institute, Newport Beach
Los Alamitos, California, United States
Pharmacology Research Institute, Newport Beach
Newport Beach, California, United States
Medical Center for Clinical Research
San Diego, California, United States
California Clinical Trials
San Diego, California, United States
Avail Clinical Research LLC
DeLand, Florida, United States
Psychiatric Inst of Florida-Clinical Neuroscience Solutions
Orlando, Florida, United States
PharmaSite Research Inc
Baltimore, Maryland, United States
PAREXEL-Phase 1 Baltimore Harbor Hospital Center
Baltimore, Maryland, United States
Rochester Clinical Research, Inc.
Rochester, New York, United States
CNS Health Care
Memphis, Tennessee, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I5Q-MC-S001
Identifier Type: OTHER
Identifier Source: secondary_id
16235
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.